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PREDICT-PD algorithm along with subjective RBD,
smell loss, and motor impairment are useful in identi-
fying striatal pathology and that this combination is
superior to using individual features.
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ABSTRACT
Background: We investigated a family that presented
with an infantile-onset chorea-predominant movement
disorder, negative for NKX2-1, ADCY5, and PDE10A
mutations. Methods: Phenotypic characterization and
trio whole-exome sequencing was carried out in the
family. Results: We identified a homozygous mutation
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affecting the GAF-B domain of the 3’,5’-cyclic nucleo-
tide phosphodiesterase PDE2A gene (c.1439A>G;
p.Asp480Gly) as the candidate novel genetic cause of
chorea in the proband. PDE2A hydrolyzes cyclic aden-
osine/guanosine monophosphate and is highly
expressed in striatal medium spiny neurons. We func-
tionally characterized the p.Asp480Gly mutation and
found that it severely decreases the enzymatic activity
of PDE2A. In addition, we showed equivalent expres-
sion in human and mouse striatum of PDE2A and its
homolog gene, PDE10A. Conclusions: We identified a
loss-of-function homozygous mutation in PDE2A associ-
ated to early-onset chorea. Our findings possibly
strengthen the role of cyclic adenosine monophosphate
and cyclic guanosine monophosphate metabolism in
striatal medium spiny neurons as a crucial pathophysio-
logical mechanism in hyperkinetic movement disorders.
VC 2018 The Authors. Movement Disorders published by
Wiley Periodicals, Inc. on behalf of International Parkin-
son and Movement Disorder Society.
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Chorea is a hyperkinetic movement disorder character-
ized by an excess of brief, continuous, unpatterned invol-
untary movements.1 Focal lesions of the striatum,
degeneration, or functional dysregulation of medium spiny
neurons (MSNs) that constitute 95% of the striatal cells
are considered to be crucially implicated in the pathophysi-
ology of choreic movements.2-5 A variety of acquired
causes may underlie chorea in the pediatric age group (e.g.,
Sydenham chorea, cerebral palsy), but genetic etiologies
also play a role in different early-onset choreic syndromes.
Among the possible genetic causes, dominantly inherited
(or de novo) mutations in NKX2-1 (MIM #600635),
encoding a transcription factor essential for striatum devel-
opment, cause a variable spectrum of childhood-onset dis-
orders ranging from choreoathetosis to myoclonus,
congenital hypothyroidism, and respiratory distress.6 In
addition, de novo or dominantly inherited mutations in
ADCY5 (MIM #600293), encoding an enzyme crucial to
the synthesis of cyclic adenosine monophosphate (cAMP)
in MSNs, have been linked to different infantile/childhood-
onset phenotypes defined as “ADCY5-related dyskinesias”
that include nonprogressive choreiform movement disor-
ders as well as pleiotropic fluctuating/paroxysmal dyskine-
sias.7,8 Furthermore, both de novo dominant and biallelic
mutations in the PDE10A gene (MIM #610652), encoding
an enzyme involved in the hydrolysis/degradation of cAMP
and cyclic guanosine monophosphate (cGMP) in
MSNs, have been reported in patients with infantile/child-
hood-onset chorea usually exhibiting a generalized
distribution.9,10 In this study, we performed trio-based
whole-exome sequencing (WES) in a 12-year-old patient
presenting a childhood-onset chorea-predominant move-
ment disorder and identified a homozygous missense
mutation (c.1439A>G; p.Asp480Gly) in PDE2A (MIM
#602658), a gene mainly involved in brain cAMP and
cGMP metabolism and not previously associated with
human phenotypes, as the possible novel genetic cause of
chorea in the patient. Screening of genomic data from a
number (n 5 62) of similarly affected individuals did not
identify additional PDE2A likely pathogenic variants.
Materials and Methods
Genetic Analysis
The 12-year-old male patient is the second child of
unrelated healthy parents, both originally from the
Canary Island of Tenerife, and he was seen at the Hos-
pital Sant Joan de Deu in Barcelona (Spain) by move-
ment disorder specialists because of a history of early-
onset fluctuating dyskinesia associated with chronic
chorea. To molecularly investigate the cause of the dis-
ease in this child, the 4 family members (Fig. 1A) donat-
ed their blood samples after informed consent and
DNA was extracted using standard procedures. A trio
WES study of the family (Fig. 1A, I-1, I-2, II-2) was
then performed. Genomic pipeline and variants annota-
tion were carried out as previously reported11,12 and
described in the Supplementary Information. In accord
with the pedigree and phenotype, our filtering strategy
prioritized rare (<1% in public databases, including
1000 Genomes project and Exome Aggregation Con-
sortium [ExAC v0.2]) variants that were fitting a de
novo or a recessive model (Supplementary Informa-
tion). We also performed homozygosity mapping in the
family (Supplementary Information).
Functional Characterization of the
p.Asp480Gly PDE2A Mutation
Materials
cAMP and cGMP were purchased from Sigma-Aldrich
(St. Louis, MO). The [3H]-labeled nucleotides, [3H]cAMP
(31.3 Ci/mmol) and [3H]cGMP (14.3 Ci/mmol), were
purchased from PerkinElmer (Waltham, MA).
Cloning and Expression of Constructs
Complementary DNA for human PDE2A3 (Gen-
Bank: U67733) was used as a template and the
mutant, c.1439A>G; p.(Asp480Gly), was constructed
by site-directed point mutation. All constructs were
cloned into the pcDNA3.1(1)neo vector (Thermo
Fisher Scientific, Inc., Waltham, MA) and transfected
into COS-7 cells (ECACC, Salisbury, UK). The mem-
brane fractions were used for the enzyme assay.
In Vitro Phosphodiesterase Enzyme Assay
Phosphodiesterase (PDE) activities were measured
using a scintillation proximity assay (SPA)-based
method.13 In this assay, the product of the PDE reac-
tion, either [3H]AMP or [3H]GMP, can bind directly
A H O M O Z Y G O U S P D E 2 A M U T A T I O N C A U S I N G C H O R E A
Movement Disorders, Vol. 33, No. 3, 2018 483
to yttrium silicate PDE SPA beads (GE Healthcare
Ltd., Little Chalfont, UK), leading to light emission
from the scintillant in the beads. The enzyme assays
were conducted in a buffer (50 mM of HEPES-NaOH,
8.3 mM of MgCl2, 1.7 mM of ethylene glycol
tetraacetic acid, and 0.1% bovine serum albumin
[pH 7.4]) in 96-well half-area plates (Corning Inc.,
Corning, NY). For enzyme studies, reaction was con-
ducted at the presence of the indicated concentrations
of substrate using a mixture (20 mL) of [3H]-labeled
FIG. 1. Family tree and genetic and functional studies. (A) Family tree. (B) Chromatograms from Sanger sequencing from individuals I-1, I-2, and II-
2. (C) Genetic analysis showing the homozygous block of the proband on chromosome 11 (chr11: 63138482-76853783). (D) Multiple-sequence
alignment showing conservation of protein sequence across species and PDE homolog (PDE10A) in the GAF-B domain, in which the p.Asp480Gly
homozygous mutation (underlined) was found. (E) Catalytic activity of wild-type and mutant PDE2A in the presence of 70 nM of [3H]cAMP. (F) Cata-
lytic activity of wild-type and mutant PDE2A in the presence of 70 nM of [3H]cGMP. [Color figure can be viewed at wileyonlinelibrary.com]
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and unlabeled cAMP or [3H]-labeled and unlabeled
cGMP with the 20 mL of membrane fractions of
PDE2A-expressing COS-7 cells at 37oC, followed by
reaction termination by SPA beads addition (20 mL of
20 mg/mL). Degradation of each radiolabeled substrate
([3H]cAMP or [3H]cGMP) at the presence of various
concentrations of cold cAMP or cGMP, respectively,
was measured using the SPA-based assay method.
PDE2A Messenger RNA Expression Studies
Overall brain expression and cell-specific expression
data were initially obtained using BRAINEAC and Bac-
TRAP mice data, respectively.14,15 Then, we analyzed
in vivo PDE2A and PDE10A messenger RNA (mRNA)
expression patterns using mice and human brains, as
described in detail in the Supplementary Information.
FIG. 2. PDE2A expression studies. (A) Brain expression values of PDE2A show higher expression levels in the striatum and also other CNS regions,
especially FCTX (frontal cortex) and TCTX (temporal cortex), and less in HIPP (hippocampus), OCTX (occipital cortex), WHMT (white matter), SNIG
(substantia nigra), MEDU (medulla), THAL (thalamus), and CRBL (cerebellar cortex). (B) Expression values of PDE2A mRNA (1447707_s_at) in MSNs
of direct and indirect pathways (D1 1 and D2 1 MSNs). (C) mRNA expression analysis on mice and human brains of PDE2A and PDE10A show simi-
lar expression patterns in striatum, but different expression patterns elsewhere in mouse and human brain.
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Results
Disease onset in our patient mainly consisted in fluc-
tuating attacks of sudden falls, followed by dystonic
postures and generalized choreic movements. Subse-
quently, he developed since the age of 9 years a slowly
progressive choreic movement disorder associated with
dystonic features. In addition to his movement disor-
der, he also had language difficulties, cognitive impair-
ment (total score 44 with Kauffman Brief Intelligence
Test), and a history of interictal epileptic features
(Supplementary Information). We performed a trio-
based WES, and, after applying our filtering criteria,
we identified a number of possibly pathogenic variants
according to guidelines for variants interpretation
(Supplementary Information; Supplementary Table
1).16 The proband of our family carried a single de
novo variant in the gene, STRADA (NM_153335.5;
c.1042G>T: p.Gly348Trp); homozygous intragenic
deletions (or biallelic truncating mutations) in this
gene were previously associated with polyhydramnios,
megalencephaly, distinctive facial features, and symp-
tomatic epilepsy (#MIM 611087),17,18 a phenotype
not consistent with the clinical presentation of our
patient. In addition, we identified a homozygous vari-
ant (NM_002599.4; c.1439A>G: p.Asp480Gly) in
PDE2A (#MIM 602658) as the only biallelic variant
segregating with the disease within the family. Also,
the PDE2A homozygous mutation was inherited with-
in the only significant homozygous block (chr11:
63138482-76853783) identified in the proband by
homozygosity mapping analysis (Fig. 1B–D; Supple-
mentary Information). Additionally, our in vitro func-
tional studies showed that both cAMP and cGMP
hydrolysis were markedly increased for wild-type
PDE2A compared to the p.Asp480Gly mutant
(approximately 3.7-fold and 6.4-fold, respectively).
On the contrary, neither cAMP nor cGMP increased
enzyme activities of the mutant enzyme (Fig. 1E,F;
Supplementary Tables 2-5), indicating a severe disrup-
tion of catalytic activity of mutated PDE2A.
Discussion
The genetic analysis of this family using WES and
homozygosity mapping indicated a homozygous mis-
sense mutation in PDE2A as the most likely explanation
for the patient’s disease. This is supported by: (1) in sil-
ico pathogenic predictors, conservation, and cosegrega-
tion analysis (Supplementary Table 1; Fig. 1D); (2)
previous9,10,19 and current (Fig. 2A–C) studies, which
indicates a high (predominant) expression of PDE2A in
the striatum (qualitatively equivalent to PDE10A stria-
tal expression); (3) biological importance of the PDE2A
GAF-B domain (where the p.Asp480Gly mutation is
located) in the metabolism of cAMP and cGMP (and
implication of these cyclic nucleotides in the
pathogenesis of similar phenotypes including ADCY5-
and PDE10A-related movement disorders)5-10,20-23; and
(4) in vitro functional studies that showed a severe dis-
ruption of the mutant PDE2A enzymatic activity (Fig.
2E; Supplementary Tables 2-5).
Importantly, the amino acid involved by the muta-
tion we identified (aspartic acid at position 480) is
located in the presumed cyclic nucleotide binding
pocket of GAF-b domain.24 To assess enzyme activity
of PDE2A, we measured degradation of radiolabeled
substrate ([3H]cAMP or [3H]cGMP) and showed a sig-
nificant decrease in the hydrolytic activity of the
mutant PDE2A enzyme. Of note, we screened genomic
data from 17 individuals with childhood-onset chorea
and from 45 patients presenting fluctuating or parox-
ysmal dyskinesia and failed to identify further muta-
tions in PDE2A, suggesting that this might represent a
very rare genetic cause of early-onset choreic/hyperki-
netic movement disorders. The PDE2A p.Asp480Gly
mutation was inherited within the only homozygous
block on a shared haplotype (Supplementary Fig. 1),
indicating that this could possibly represent a founder
mutation from the genetic isolate of Canary Islands.
Supporting this Canary founder effect, in the ExAC
database (http://exac.broadinstitute.org, last accessed
October 2017) containing 60,706 individuals, the
PDE2A gene was found to be highly constrained for
missense variation (z 5 4.78), with only 27 individuals
carrying nonsynonymous (heterozygous) variants
affecting the GAF-B domain.
Of interest, monogenic etiologies underlying infantile-
and childhood-onset choreic movement disorders are
being increasingly recognized.7-10 In this regard, the iden-
tification and characterization of the ADCY5- and
PDE10A-related spectrum of disorders shed new light
on the key role of cAMP and cGMP signaling in basal
ganglia circuit and the control of movements.5-7 The
adenyl cyclase 5 enzyme catalyzes cAMP formation and
pathogenic ADCY5 mutations might thus increase the
synthesis of cAMP because of a possible enhancement of
Ac5 enzymatic activity.5,7,8 The PDE10A enzyme is
involved in cAMP hydrolysis in MSNs, and in vitro
assessment of PDE10A mutations showed that both
dominant and recessive variants lead to a loss-of-func-
tion effect with consequent impairment of cAMP and
cGMP hydrolysis/degradation.9,10 Thus, elevated cAMP
(and possibly cGMP) intracellular levels in MSNs (either
attributed to increased synthesis or reduced hydrolysis)
could represent a central mechanism for molecular path-
ogenesis of different hyperkinetic movement disorders.5
Notably, the cyclic nucleotides cAMP and cGMP are
ubiquitous intracellular second messengers regulating a
variety of biological processes.25 The intracellular con-
centration of these molecules is modulated by the activity
of PDEs, a class of several different enzymes currently
grouped overall in 11 families, and, among the PDEs,
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PDE2A and PDE10A are among the most highly
enriched in the striatum.26,27 PDE2A expression is high-
est in the striatum, cortex, and hippocampus compared
to other central nervous system (CNS) regions (Fig. 2A),
with similar expression in direct and indirect MSN path-
ways (Fig. 2B). Furthermore, our comparative expression
analysis on human and mice brain found that striatal
mRNA levels of PDE2A and its paralogue gene,
PDE10A, are qualitatively equivalent, with a more gen-
eralized PDE2A expression in some additional CNS
regions (Fig. 2C). These PDE2A more generalized brain
expression patterns may explain the broad neurological
features (including interictal epileptic discharges and cog-
nitive impairment) we observed in our patient in addition
to his movement disorder. Notably, the PDE2A enzyme
is a dual-substrate PDE that hydrolyzes both cAMP and
cGMP and has two N-terminal tandem noncatalytic
domains, named GAF-A and GAFB.18,19,28 PDE2A
exhibits a low level of basal hydrolytic activity that is
further stimulated when its GAF-B domain binds cAMP
or cGMP.20,21,29 However, it is most likely that only
cGMP binds the PDE2A GAF-B domain in vivo, thereby
selectively stimulating its cAMP hydrolytic activity.20,30
In conclusion, results from our genetic and function-
al studies indicate a PDE2A p.Asp480Gly homozy-
gous loss-of-function mutation as the likely genetic
cause of early-onset hereditary chorea in our family,
thus possibly expanding the genetic aetiology of early-
onset choreic/hyperkinetic movement disorders associ-
ated to abnormal c-AMP and c-GMP metabolism in
striatal MSNs.
Legend to the Video
The episodes of dyskinesia initiated with neck exten-
sion, backward falling, and dystonic posturing of the
four limbs, followed by choreic movements, facial gri-
macing, blinking, and orolingual movements. During
execution of motor task (writing), the child showed a
complex hyperkinetic movement consisting in baseline
chorea associated with dystonic posturing (predomi-
nantly in the left foot).
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